New study targets ovarian cancer treatment in black women

NCT ID NCT06412120

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Niraparib blocks cancer cells from repairing their DNA, which may slow or stop tumor growth. Researchers will track side effects and explore how genetic and environmental factors affect the drug's safety and metabolism. About 70 participants will take niraparib for up to 3 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ahmadu Bello University Teaching Hospital (ABUTH)

    RECRUITING

    Zaria, Kaduna State, Nigeria

    Contact Email: •••••@•••••

    Contact

  • Broward Health

    RECRUITING

    Fort Lauderdale, Florida, 33316, United States

    Contact Email: •••••@•••••

    Contact

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.